


Docetaxel GETUG-15

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit

#### Serious and disabling adverse effects



#### Other adjustments



Docetaxel GETUG-15

### SCORE

#### CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: In combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer  
Experimental Arm: Docetaxel + ADT (androgen deprivation therapy)  
Control Arm: ADT



